Incidence of paediatric multiple sclerosis and other acquired demyelinating syndromes: 10-year follow-up surveillance study.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
24
09
2021
received:
05
05
2021
accepted:
27
09
2021
pubmed:
26
10
2021
medline:
28
4
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
To describe a 10-year follow-up of children (<16y) with acquired demyelinating syndromes (ADS) from a UK-wide prospective surveillance study. Diagnoses were retrieved from the patients' records via the patients' paediatric or adult neurologist using a questionnaire. Demyelinating phenotypes at follow-up were classified by an expert review panel. Twenty-four out of 125 (19.2%) children (64 males, 61 females; median age 10y, range 1y 4mo-15y 11mo), identified in the original study, were diagnosed with multiple sclerosis (incidence of 2.04/million children/year); 23 of 24 fulfilled 2017 McDonald criteria at onset. Aquaporin-4-antibody neuromyelitis optica spectrum disorders were diagnosed in three (2.4%, 0.26/million children/year), and relapsing myelin oligodendrocyte glycoprotein antibody-associated disease in five (4%, 0.43/million children/year). Three out of 125 seronegative patients relapsed and 85 of 125 (68%) remained monophasic over 10 years. Five of 125 patients (4%) originally diagnosed with ADS were reclassified during follow-up: three children diagnosed initially with acute disseminated encephalomyelitis were subsequently diagnosed with acute necrotising encephalopathy (RAN-binding protein 2 mutation), primary haemophagocytic lymphohistiocytosis (Munc 13-4 gene inversion), and anti-N-methyl-d-aspartate receptor encephalitis. One child initially diagnosed with optic neuritis was later diagnosed with vitamin B12 deficiency, and one presenting with transverse myelitis was subsequently diagnosed with Sjögren syndrome. The majority of ADS presentations in children are monophasic, even at 10-year follow-up. Given the implications for treatment strategies, multiple sclerosis and central nervous system autoantibody mimics warrant extensive investigation.
Substances chimiques
Autoantibodies
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-508Subventions
Organisme : Medical Research Council
ID : MR/T024437/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : GN79832
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 216613/Z/19/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Mac Keith Press.
Références
Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013; 19: 1261-7.
O'Mahony J, Marrie RA, Laporte A, Yeh EA, Bar-Or A, Phan C, et al. Recovery from central nervous system acute demyelination in children. Pediatrics. 2015; 136: e115-23.
Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014; 13: 936-48.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17: 162-73.
Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adoles Health. 2018; 2: 191-204.
Hacohen Y, Brownlee W, Mankad K, Chong WKK, Thompson A, Lim M, et al. Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. Mult Scler. 2020; 26: 1372-80.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85: 177-89.
Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm. 2015; 2: e81.
Baumann M, Hennes E-M, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler. 2016; 22: 1821-29.
Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012; 69: 752-6.
Huppke P, Rostasy K, Karenfort M, Huppke B, Seidl R, Leiz S, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler. 2013; 19: 941-6.
Fadda G, Armangue T, Hacohen Y, Chitnis T, Banwell B. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 2021; 20: 136-49.
Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler. 2013; 19: 76-86.
Osmond C, Breslow NE, Day NE. Statistical methods in cancer research, vol. 2, the design and analysis of cohort studies. Series A (Statistics in Society). J R Stat Soc. 1990; 153: 102. http://dx.doi.org/10.2307/2983104
Whitworth A. Population estimates for UK, England and Wales Scotland, and Northern Ireland Mid-2010 population estimates. Office for National Statistics, 2011. http://www.ons.gov.uk. Accessed 11 May 2011.
van der Vuurst de Vries RM, Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP, et al. Application of the 2017 Revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol. 2018; 75: 1392-8.
Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc. 2018; 2: 191-204.
Waldman A, Ness J, Pohl D, Simone IL, Anlar B, Amato MP, et al. Pediatric multiple sclerosis: clinical features and outcome. Neurology. 2016; 87: S74-81.
Dell’Avvento S, Sotgiu MA, Manca S, Sotgiu G, Sotgiu S. Epidemiology of multiple sclerosis in the pediatric population of Sardinia. Italy. Eur J Pediatr. 2016; 175: 19-29.
Eusebi A, Zara P, Zarbo IR, Festa S, Dessì V, Pes V, et al. Long-term trajectory of acquired demyelinating syndrome and multiple sclerosis in children. Dev Med Child Neurol. 2021; 63: 1059-65.
Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. 2019; 21: 2.
Waters P, Fadda G, Woodhall M, O’Mahony J, Brown RA, Castro DA, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurology. 2020;77:82. http://dx.doi.org/10.1001/jamaneurol.2019.2940
Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018; 75: 478-87.
De Mol C, Wong Y, van Pelt E, Wokke B, Siepman T, Neuteboom R, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020; 26: 806-14.
Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021; 96: 59-77.
Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol. 2012; 19: 655-59.
Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol. 2013; 260: 2134-7.
O'Mahony J, Bar-Or A, Arnold DL, Sadovnick AD, Marrie RA, Banwell B, et al. Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program. J Child Neurol. 2013; 28: 184-97.